Bright Minds Biosciences, a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, announced that studies conducted with its BMB proprietary 5-HT2C agonist, BMB-101, showed efficacy in rodent models of Dravet Syndrome /Epilepsy.
August 18, 2021
· 5 min read